Receptors, Metabotropic Glutamate
J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure
Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders
Actionable Insights Powered by AI
Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders